LYNPARZA (olaparib)

LynparzaTM (olaparib) is a first‐in‐class PARP inhibitor (PARPi) that allows women with BRCA mutated (BRCAm) platinum‐sensitive relapsed high-grade serous ovarian cancer to extend progression‐free survival (PFS).1-3

About Study 19

TSST

A comparison chart between Placebo and Lynparza about TSST
A comparison chart between Placebo and Lynparza about TSST

In patients with a BRCA mutation, the time from randomisation to start of second subsequent therapy or death (TSST)‡‡ was 6.7 months longer for Lynparza treated patients vs placebo (HR 0.41; 95% CI 0.28-0.62; p<0.0001; median 22.0 months vs 15.3 months).35

‡‡An exploratory retrospective analysis.